3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Conditions
Melanoma
1
Carcinoma, Basal Cell
1
Interventions
pembrolizumab
157
Nivolumab
132
Ipilimumab
77
Cyclophosphamide
46
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
28
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
21
fludarabine phosphate
20
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
aldesleukin
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lenvatinib
11
Bevacizumab
11
lifileucel
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
BO-112
×
Dermatologic
×
1 year
×
Clear all
NCT06422936
2026-01-26
SPOTLIGHT204
Highlight Therapeutics
Phase 2
Active not recruiting
60 enrolled
NCT04570332
2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2
Completed
42 enrolled
12 charts